Compare PENG & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PENG | OPK |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2017 | 1995 |
| Metric | PENG | OPK |
|---|---|---|
| Price | $20.37 | $1.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $27.50 | $2.28 |
| AVG Volume (30 Days) | 798.6K | ★ 3.2M |
| Earning Date | 01-06-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,368,794,000.00 | $642,067,000.00 |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $15.95 | N/A |
| P/E Ratio | $72.46 | ★ N/A |
| Revenue Growth | ★ 16.91 | N/A |
| 52 Week Low | $14.20 | $1.11 |
| 52 Week High | $29.80 | $2.04 |
| Indicator | PENG | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 39.62 |
| Support Level | $19.65 | $1.29 |
| Resistance Level | $20.27 | $1.37 |
| Average True Range (ATR) | 0.64 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 26.71 | 10.06 |
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.